Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study.

Al B. Benson,Jonathan R. Strosberg,Vijay N. Joish,Samyukta Dharba,Dipa Sapre,Pablo Lapuerta

Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study.

2020

Al B. Benson
Jonathan R. Strosberg
Vijay N. Joish
Samyukta Dharba
Dipa Sapre
Pablo Lapuerta

OBJECTIVES: We evaluated carcinoid syndrome (CS) symptoms and the real-world effectiveness of telotristat ethyl (TE) among patients with /=1 monthly follow-up within 3 months. Symptoms for patients averaging

Keywords:

Telotristat ethyl
Observational study
Neuroendocrine tumors
Bowel movement frequency
Internal medicine
Endocrinology
Biology
Diabetes mellitus
Carcinoid syndrome
Nausea
Defecation
Abdominal pain

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations